These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2005-000693-45 A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and Rituximab bad-data
Completed, but no date 2005-001500-39 A phase II GISL study of R-HyperCVAD in the treatment of patients with Mantle cell Lymphoma bad-data
Ongoing 2005-005218-19 Randomised Study Comparing an Immuno-Chemotherapy with 6 Cycles of the Monoclonal anti-CD20 Antibody Rituximab in Combination with 6 Cycles of Chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vi... not-yet-due
Completed, but no date 2006-001164-24 MAINTENANCE TREATMENT WITH ALEMTUZUMAB Campath AS AN ALTERNATIVE TO ALLOGENIC TRANSPLANTATION IN PATIENTS WITHOUT COMPATIBLE DONOR IN PATIENTS WITH PERIPHERAL T CELL LYMPHOMA bad-data
Not reported 2006-002521-23 Phase II study of VELCADE in combination with Rituximab in patients with relapsed or progressed Non Hodgkin's Follicular Lymphoma 2015-08-07 due-trials
Completed, but no date 2006-003189-33 Phase II study with Palonosetron alone in preventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non HodgkinÂ’s Lymphomas who underwent moderately emetogenic chemothe... bad-data
Completed, but no date 2006-006915-61 Prospective Randomized Trial of Immediate Treatment with Campath versus Deferred Therapy in Patients with Previously Untreated Binet Stage A B-Cell Chronic Lymphocytic Leukemia at High Risk for Di... bad-data
Ongoing 2007-006064-30 A randomised phase III trial to assess response adapted therapy using FDG-PET imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma not-yet-due
Not reported 2008-001591-80 PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA 2015-04-16 due-trials
Completed, but no date 2009-015974-36 Phase II prospective study on high dose myeloablative therapy, with peripheral stem cell support, in elderly patients (>=65 e <76 years) with aggressive relapsed or refractory non Hodgkin lymphoma bad-data